U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both ...

Highlights,Institutional investors have adjusted their holdings in Eli Lilly and Company, with several firms increasing ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Network highlights graduates shaping the fields of law, banking, finance, education, health care, media, science, technology ...

House Bill 1879 passed unanimously March 4 on a 95-0 vote, according to the chamber's website. State senators will now ...

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Eli Lilly (LLY) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%.

Eli Lilly Chief Executive David Ricks annual compensation rose to $29.2 million in 2024, a 10% increase from the $26.2 million he received a year earlier.

Teladoc and LifeMD are partnering with drugmaker Eli Lilly to offer the weight loss drug Zepbound directly to self-paying patients. The two telehealth companies said Thursday they’re working ...